White Paper
IQVIA Pharma Deals: Review of 2022
IQVIA Pharma Deals
Mar 14, 2023

The IQVIA Pharma Deals Review of 2022 provides an insightful overview of deal activity in 2022, as well as an outlook for 2023.

Key information provided includes the following:

    • Top M&A and partnership deals in 2022
    • Deal activity by therapeutic area and development phase
    • Deal value analysis of M&A, licensing and R&D deals
    • Deal activity rankings of the top pharmaceutical companies

Report key highlights:

    • Amid much market and economic turbulence, deal activity in the life sciences sector fell by 25% from 2021 to 2022, as many companies opted to pursue a wait and see approach and others were reluctant to accept discounted valuations.
    • The volume of life science M&A deals announced in 2022 fell 30% from the frenetic pace of 2021 as pricing mismatches prevailed and the major players generally took a cautious approach to deal expenditure.
    • After reaching a 5-year high in 2021, licensing activity in the life sciences sector dropped 25% from 2021 to 2022 as streamlined companies focused their partnering interests on high-growth opportunities and COVID-19-related licensing activity subsided.

Please fill in your details on the left to download the article.

Related solutions

Contact Us